The EU Commission sends a Statement of Objections to a pharmaceutical company over abusive patent filings and disparagement of generic competitors (Teva)

Ross, Steve; L'Ecluse, Peter

Previous article The EU Commission issues Statement of Objections against a pharmaceutical company over alleged abuse of dominance consisting of misuse of divisional patents and a disparagement campaign against its closest competitor (Teva) Next article The EU Commission sends a Statement of Objections to a drug manufacturer accusing it of regulatory gaming and denigration of competitors in breach of Article 102 (Teva)

10 Oct 2022

The EU Commission sends a Statement of Objections to a pharmaceutical company over abusive patent filings and disparagement of generic competitors (Teva)

KEYWORDS

Reference

EU Commission, Teva, Press Release, 10 October 2022

On 10 October 2022, the European Commission (the “Commission”) announced that it had sent a Statement of Objections to Teva, a pharmaceutical company marketing Copaxone®, a medicine indicated for the treatment of specific forms of multiple sclerosis. The Statement of Objections

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Authors

Steve Ross
Van Bael & Bellis (Brussels)

Belgium 22 contributions 4146 visits
Peter L’Ecluse
Van Bael & Bellis (Brussels)

Belgium 142 contributions 47919 visits

Quotation

Steve Ross, Peter L'Ecluse, The EU Commission sends a Statement of Objections to a pharmaceutical company over abusive patent filings and disparagement of generic competitors (Teva), 10 October 2022, e-Competitions October 2022, Art. N° 109413

Visites 49